Published in J Biol Chem on January 10, 1974
Protein kinase activity in rat testis interstitial tissue. Effect of luteinizing hormone and other factors. Biochem J (1976) 0.99
Action of feedback regulator on adenylate cyclase. Proc Natl Acad Sci U S A (1975) 0.96
Stimulus-secretion coupling: role of cyclic AMP, cyclic GMP and calcium in mediating enzyme (kallikrein) secretion in the submandibular gland. J Physiol (1976) 0.87
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Isolation of an RNA with the properties of haemoglobin messenger. Nature (1969) 3.53
Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord (1997) 2.67
Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol (1997) 2.58
The thalamus as a neuronal oscillator. Brain Res (1984) 2.50
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate (1983) 2.29
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell (1999) 2.17
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys (1997) 2.10
Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol (1991) 2.07
A model for an estimate in vivo of the ionic basis of presynaptic inhibition: an intracellular analysis of the GABA-induced depolarization in rat dorsal root ganglia. Brain Res (1976) 1.79
Poly(ADP-ribose)polymerase: a novel finger protein. Nucleic Acids Res (1989) 1.72
The baculovirus p35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem (1995) 1.72
Assignment of the human 3 beta-hydroxysteroid dehydrogenase gene (HSDB3) to the p13 band of chromosome 1. Cytogenet Cell Genet (1989) 1.70
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab (1994) 1.66
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med (1982) 1.65
Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem (1988) 1.60
Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med (1994) 1.59
Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem (2000) 1.59
Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J Endocrinol (2000) 1.57
Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology (1997) 1.53
Sudden infant deaths in sitting devices. Arch Dis Child (2007) 1.50
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril (1994) 1.50
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med (1992) 1.50
Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet (1984) 1.49
The synthesis and opiate activity of beta-endorphin. Biochem Biophys Res Commun (1976) 1.46
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat (2008) 1.45
Clinical and sleep laboratory study of narcoleptic symptoms in multiple sclerosis. Neurology (1987) 1.45
Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer (2003) 1.44
The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care (1996) 1.43
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet (1996) 1.42
Prostate cancer. Lancet (1994) 1.40
Fast and slow spindle involvement in the consolidation of a new motor sequence. Behav Brain Res (2010) 1.38
Immunohistochemical localization of beta-lipotropic hormone in the pituitary gland. Endocrinology (1977) 1.38
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution. Structure (1995) 1.30
Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J Biol Chem (1978) 1.26
Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol (1985) 1.26
Molecular cloning of human type 3 3 alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophys Res Commun (1996) 1.25
Rat vas deferens: a specific bioassay for endogenous opioid peptides. Br J Pharmacol (1978) 1.24
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut (2006) 1.22
Infection of human monocytes/macrophages by HIV-1: effect on secretion of IL-1 activity. Immunology (1988) 1.22
Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav (1988) 1.21
Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem (1989) 1.18
Development of the hypothalamic-pituitary-thyroid axis in the neonatal rat. Endocrinology (1975) 1.16
Unique features of the basal cells of human prostate epithelium. Microsc Res Tech (2000) 1.16
Alpha 1-acid glycoprotein potentiates lipopolysaccharide-induced secretion of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha by human monocytes and alveolar and peritoneal macrophages. Eur J Immunol (1992) 1.15
Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. J Biol Chem (1990) 1.15
The single mutation Trp35-->Ala in the 35-40 redox site of Chlamydomonas reinhardtii thioredoxin h affects its biochemical activity and the pH dependence of C36-C39 1H-13C NMR. Eur J Biochem (1998) 1.14
Reproducibility, bioinformatic analysis and power of the SAGE method to evaluate changes in transcriptome. Nucleic Acids Res (2005) 1.14
Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology (1999) 1.14
In vitro interactions of gastrointestinal hormones on cyclic adenosine 3':5'-monophosphate levels and amylase output in the rat pancreas. Gastroenterology (1975) 1.12
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun (1976) 1.12
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate (1995) 1.11
Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J Steroid Biochem Mol Biol (1992) 1.11
Ocular toxicity of Anandron in patients treated for prostatic cancer. Br J Ophthalmol (1986) 1.10
The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology (1985) 1.10
Characterization of a new strain of HHV-6 (HHV-6SF) recovered from the saliva of an HIV-infected individual. Virology (1990) 1.08
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol (1996) 1.08
Chromaffin cell scinderin, a novel calcium-dependent actin filament-severing protein. EMBO J (1990) 1.08
The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab (2004) 1.07
Localisation of 15-hydroxy prostaglandin dehydrogenase (PGDH) and steroidogenic enzymes in the equine placenta. Equine Vet J (1995) 1.07
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther (2006) 1.07
Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex. Mol Cell Biol (1999) 1.05
Impairment of lymphocyte proliferative responses and interleukin-2 production in susceptible (C57BL/6) mice infected with Salmonella typhimurium. Immunology (1986) 1.05
The distribution of spectrin along the membranes of normal and echinocytic human erythrocytes. J Cell Sci (1978) 1.05
CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol (2001) 1.04
Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol (1991) 1.03
Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEB J (1998) 1.03
Studies on the inhibitory action of opiate compounds in isolated bovine adrenal chromaffin cells: noninvolvement of stereospecific opiate binding sites. J Neurochem (1981) 1.03
Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa. Clin Neuropharmacol (1986) 1.03
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem (1985) 1.02
Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res (1986) 1.02
Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis (2007) 1.02
Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology (1989) 1.02
Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Urology (1997) 1.02
Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action. Proc Natl Acad Sci U S A (1982) 1.02
Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res (1998) 1.02
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res (1991) 1.02
Structure of the human 3alpha-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25-A resolution. J Biol Chem (2001) 1.01
Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism (1995) 1.01
Selective effect of androgens on LH and FSH release in anterior pituitary cells in culture. Endocrinology (1976) 1.01
32P-labellingof haemoglobin messenger and other reticulocyte ribonucleic acids with polynucleotide phosphokinase in iro. Biochem J (1969) 1.00
Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes. Mol Endocrinol (1990) 1.00
Corticotropin-releasing factor stimulates accumulation of adenosine 3', 5'-monophosphate in rat pituitary corticotrophs. Science (1982) 1.00
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism (1987) 1.00
Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology (1999) 1.00
Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. Mult Scler (2002) 1.00
Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells. Cancer Res (1991) 0.99
Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate (2000) 0.99
Possible muscarinic regulation of catecholamine secretion mediated by cyclic GMP in isolated bovine adrenal chromaffin cells. Biochem Pharmacol (1981) 0.99
Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. J Endocrinol (1996) 0.99
Pharmacological manipulation of Ins(1,4,5)P3 signaling mimics preconditioning in rabbit heart. Am J Physiol (1999) 0.98
Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science (1978) 0.98
Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat (1988) 0.98
Complete androgen blockade for the treatment of prostate cancer. Important Adv Oncol (1985) 0.98